Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE – Get Rating) in a research report report published on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Ampio Pharmaceuticals Trading Down 26.7 %

NYSEAMERICAN:AMPE opened at $0.22 on Wednesday. Ampio Pharmaceuticals has a twelve month low of $0.20 and a twelve month high of $9.71. The firm has a market capitalization of $3.32 million, a price-to-earnings ratio of -0.12 and a beta of 1.48. The firm’s fifty day simple moving average is $0.29 and its 200 day simple moving average is $0.20.

Hedge Funds Weigh In On Ampio Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Advisers LP raised its stake in shares of Ampio Pharmaceuticals by 304.3% in the 3rd quarter. Two Sigma Advisers LP now owns 432,216 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 325,300 shares in the last quarter. Shilanski & Associates Inc. acquired a new stake in shares of Ampio Pharmaceuticals in the 3rd quarter valued at about $57,000. Price T Rowe Associates Inc. MD raised its stake in shares of Ampio Pharmaceuticals by 73.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 166,979 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Ampio Pharmaceuticals in the 2nd quarter valued at about $72,000. Finally, Bank of Montreal Can acquired a new stake in shares of Ampio Pharmaceuticals in the 1st quarter valued at about $168,000. Institutional investors and hedge funds own 19.82% of the company’s stock.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.